Evidence map›Paper›PMID 38735481›Full record

Trial reportJournal of substance use and addiction treatment2024

Examining cocaine use reductions and long-term outcomes in two clinical trials of continuing care for cocaine dependence.

Victoria R Votaw, Felicia R Tuchman, Corey R Roos, Hanna M Hebden, James R McKay, Brian D Kiluk, Katie Witkiewitz

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of substance use and addiction treatment, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Victoria R VotawDepartment of Psychology, University of New Mexico, Albuquerque, NM, United States of America; Center on Alcohol, Substance use, And Addictions (CASAA), University of New Mexico, Albuquerque, NM, United States of America; Department of Psychiatry, Harvard Medical School, Boston, MA, United States of America; Division of Depression and Anxiety Disorders, McLean Hospital, Belmont, MA, United States of America. Electronic address: vvotaw@mclean.harvard.edu.
Felicia R TuchmanDepartment of Psychology, University of New Mexico, Albuquerque, NM, United States of America.
Corey R RoosDepartment of Psychiatry, Yale School of Medicine, New Haven, CT, United States of America.
Hanna M HebdenDepartment of Psychology, University of New Mexico, Albuquerque, NM, United States of America; Center on Alcohol, Substance use, And Addictions (CASAA), University of New Mexico, Albuquerque, NM, United States of America.
James R McKayDepartment of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, United States of America; Center of Excellence in Substance Addiction Treatment and Education (CEASATE), Corporal Michael J. Crescenz Philadelphia VA Medical Center, Philadelphia, PA, United States of America.
Brian D KilukDepartment of Psychiatry, Yale School of Medicine, New Haven, CT, United States of America.
Katie WitkiewitzDepartment of Psychology, University of New Mexico, Albuquerque, NM, United States of America; Center on Alcohol, Substance use, And Addictions (CASAA), University of New Mexico, Albuquerque, NM, United States of America.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Alcohol Research Training: Methods & MechanismsT32AA018108 · NIAAA · UNIVERSITY OF NEW MEXICO · PI Katie A Witkiewitz · 2010 to 2026
$5.6M
Effectiveness of Extended Treatments for Drug DependenceR01DA020623 · NIDA · UNIVERSITY OF PENNSYLVANIA · PI MCKAY, JAMES R. · 2006 to 2010
$3.6M
Precision Medicine and Recovery in a Telehealth Treatment Program for Alcohol Use DisorderR01AA022328 · NIAAA · UNIVERSITY OF NEW MEXICO · PI Katie A Witkiewitz · 2013 to 2026
$3.1M
Mechanisms of Behavior Change in Alcohol Use Disorder TreatmentR01AA025539 · NIAAA · UNIVERSITY OF NEW MEXICO · PI TOFIGHI, DAVOOD, WITKIEWITZ, KATIE A · 2017 to 2021
$2.1M
Adaptive Treatment Models for the Management of Drug Use DisordersK24DA029062 · NIDA · UNIVERSITY OF PENNSYLVANIA · PI MCKAY, JAMES R. · 2010 to 2021
$1.6M
Web-Based Mindfulness Treatment to Prevent Relapse to Substance UseK23AT011342 · NCCIH · YALE UNIVERSITY · PI ROOS, COREY · 2020 to 2024
$823k
AFTERCARE FOR COCAINE PATIENTS--EFFECTIVENESS AND COSTSR01DA010262 · NIDA · UNIVERSITY OF PENNSYLVANIA · PI MCKAY, JAMES R · 1997 to 2001
$685k
EFFICACY AND COST EFFECTIVENESS OF AFTERCARER01AA010341 · NIAAA · UNIVERSITY OF PENNSYLVANIA · PI MCKAY, JAMES R · 1996 to 2000
$447k
Validating Reward and Relief Drinking Phenotypes: A Multimethod AssessmentF31AA029266 · NIAAA · UNIVERSITY OF NEW MEXICO · PI VOTAW, VICTORIA · 2021 to 2022
$77k
NCATS NIH HHS UL1 TR001863NCCIH NIH HHS K23 AT011342NIAAA NIH HHS F31 AA029266NIAAA NIH HHS R01 AA010341NIAAA NIH HHS R01 AA022328NIAAA NIH HHS R01 AA025539NIAAA NIH HHS T32 AA018108NIDA NIH HHS K24 DA029062NIDA NIH HHS R01 DA010262NIDA NIH HHS R01 DA020623
6 · The paper itself

Abstract

backgroundThere is a need to identify clinically meaningful non-abstinent endpoints for cocaine use disorder (CUD) clinical trials. In this study, we sought to replicate and extend prior work validating reductions in cocaine use frequency levels as an endpoint by examining associations between reductions in cocaine use frequency and long-term functioning outcomes.

methodsWe conducted a secondary analysis of two randomized clinical trials (N = 445; 77.5 % male; mean age = 42.18 years; 86.5 % Black, 10.8 % non-Hispanic white) that evaluated telephone-based continuing care for a 12- and 24-month period. Cocaine use frequency levels, measured with the Timeline Followback, were (1) abstinence (no past-month cocaine use), (2) low-frequency use (1-4 days of use/month), and (3) high-frequency use (5+ days of use/month).

resultsAmong those who completed the 12-month follow-up (n = 392), most reduced from high-frequency use at baseline to abstinence at the 12-month follow-up (n = 243; 62.0 %). An additional 21.2 % (n = 83) reported either high-to-low-frequency use (n = 35; 8.9 %) or low use-to-abstinence (n = 48; 12.2 %); 16.8 % of participants (n = 66) did not change or increased their cocaine frequency level. Compared to those who had no change/increases in frequency levels, at least a one-level reduction from baseline to 12-month follow-up (i.e., high-to-low-frequency use, high-to-abstinence, low-to-abstinence) was concurrently associated with lower levels of negative consequences at the 12-month follow-up and prospectively with lower levels of cocaine use and consequences at 24-month follow-up, with effect sizes in the medium-to-large range. Those who reduced to abstinence generally had fewer drug use consequences at the 12-month follow-up than those who reduced to a low-frequency level; however, these groups did not significantly differ on any outcomes at the 24-month follow-up.

conclusionsCategorical reductions in cocaine use frequency levels, including those short of abstinence, are associated with less cocaine use and lower problem severity up to two years following treatment entry. Low-frequency cocaine use following the initial treatment phase does not appear to forebode worsening functioning, such as escalations in cocaine use.

Indexed as

Cocaine-Related DisordersAdultContinuity of Patient CareFemaleFollow-Up StudiesHumansMaleMiddle AgedTelephoneTime FactorsTreatment OutcomeCocaine use disorderEndpointsHarm reductionNon-abstinence endpoints

Identifiers

PMID38735481
PMCPMC11180556

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.